CONCLUSIONS Antihypertensive treatment reduces the risk of mortality and cardiovascular morbidity in people with diabetes mellitus and a systolic blood pressure more than 140 mm Hg .
If systolic blood pressure is less than 140 mm Hg , however , further treatment is associated with an increased risk of cardiovascular death , with no observed benefit
OBJECTIVE To assess the effect of antihypertensive treatment on mortality and cardiovascular morbidity in people with diabetes mellitus , at different blood pressure levels .
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Blood-pressure and cholesterol lowering in persons without cardiovascular disease Elevated blood pressure and elevated low-density lipoprotein ( LDL ) cholesterol increase the risk of cardiovascular disease . Lowering both should reduce the risk of cardiovascular events substantially . This proposition is examined in this r and omised trial in which patients without cardiovascular disease were r and omised to receive such treatments compared with placebos . The combination of rosuvastatin ( 10 mg per day ) , c and esartan ( 16 mg per day ) , and hydrochlorothiazide ( 12.5 mg per day ) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease .  Muscle weakness and dizziness were more common in the combined therapy group , but the rate of discontinuation was similar in the two groups
CONCLUSIONS Antihypertensive treatment reduces the risk of mortality and cardiovascular morbidity in people with diabetes mellitus and a systolic blood pressure more than 140 mm Hg .
If systolic blood pressure is less than 140 mm Hg , however , further treatment is associated with an increased risk of cardiovascular death , with no observed benefit
OBJECTIVE To assess the effect of antihypertensive treatment on mortality and cardiovascular morbidity in people with diabetes mellitus , at different blood pressure levels .